Hospital Universitario Rio Hortega — Clinical Trial Site

59 Registered trials

25 Currently recruiting

Organisation

Hospital Universitario Rio Hortega

Location

Valladolid, Spain

Identifier

ORG-100039573

Address

Calle Dulzaina 2, 47012, Spain

Departments

#3412 - Medicina interna
3412: Reumatología
Anestesiología y Reanimación
Aparato Digestivo
Autoinmmune Diseases
Cirugía
Cirugía general
Dermatology
Digestive
Digestivo
Endocrinología
Gastroenterology
Hematología
Hematology
Hepatology department
Hepatology Service
Hospital Rio Hortega (#1)
Intensive Medicine
Internal Medicine
Medical Doctor
Medicina interna
N/A
Neumología
Neurologia
Ophtalmology
Ophthalmology
Ophthalmology service
Psychiatry
Psychiatry and mental health
Psychiatry service
Pulmonology
Rheumatology
Serv. De Reumatología
Servicio de Gastroenterología y Hepatología
Servicio de Hematologica
Servicio de Medicina Interna
Surgery
Urology

Clinical trials at this site (59)

Search interface

SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of… Ended

2022-502697-16-00 Neurotrophic Keratopathy 5 2023-08-29
An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended

2022-502921-16-00 Hemophilia A and B 6 2023-07-21
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Ended

2023-504238-23-00 Hepatitis B, Chronic 5 2023-01-17
An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended

2024-515185-13-00 geographic atrophy 5 2022-12-21
A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic M… Ended

2023-507208-30-00 Diabetic Macular Edema (DME) 10 2022-09-20
Study to evaluate the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in patients with type 2 d… Ended

2024-518403-22-00 Diabetes mellitus II 6 2022-06-20
Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2 Ended

2024-519691-10-00 Septic Shock 6 2022-05-27
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended

2024-510872-18-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-05-09
CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIM… Ended

2024-513123-17-00 Non-infection uveitis 5 2022-01-12
SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS Ended

2024-519633-35-00 Resectable pancreatic adenocarcinoma with risk factors 6 2021-10-25
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504991-31-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-05-06